Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Macro-Nanomedicine to Treat Metastatic Cancer

Project description

Targeting cancer metastases with a nanomedicine-based approach

The ultimate goal of the EU-funded Meta-Targeting project is to develop a novel, complex, nanomedicine-based approach that will improve the efficacy and decrease the side effects of treatment of metastatic breast cancer. The project's objective is to introduce multifunctional polymeric micelles co-loaded with three different drugs and with an imaging agent. In addition to the anti-tumour drug doxorubicin, the co-loading with the angiotensin receptor inhibitor losartan will help to improve the delivery of micelles. The co-loading with the P-glycoprotein inhibitor tariquidar will improve anti-tumour efficacy without typical side effects such as neurotoxicity. The imaging- and biopsy-based biomarkers are necessary for patient stratification, which is important for the clinical translation of cancer nanomedicines.

Objective

Metastatic cancer is a complex and highly heterogenous disease, which is very difficult to treat. The aim of the Meta-Targeting project is to establish a holistic, rational and realistic nanomedicine-based approach to improve the treatment of metastatic breast cancer. Concrete objectives are: (1) the development of polymeric micelles which can be efficiently and stably co-loaded with three different drugs and with an imaging agent; (2) the use of physical and pharmacological means to modulate the vasculature and microenvironment in tumors and metastases; (3) the identification of imaging- and biopsy-based biomarkers for patient selection; (4) the incorporation of drugs to overcome cellular and microenvironmental multidrug resistance; and (5) the implementation of multifunctional micelles to enhance the efficacy of immunotherapy. It is envisaged that micelles loaded with in-house developed doxorubicin prodrugs are able to induce immunogenic cell death in tumors and metastases without causing systemic immunodepression, that co-loading with the angiotensin receptor inhibitor losartan helps to prime tumors and metastases for improved delivery (of micelles, immunomodulatory antibodies and T cells), and that co-loading with the P-glycoprotein inhibitor tariquidar assists in inducing immunogenic cell death, while avoiding typical anti-Pgp side effects, such as neurotoxicity. Physical priming with ultrasound and microbubbles will promote the delivery of micelles, antibodies and T cells to and into primary tumors. Imaging- and biopsy-based biomarkers are needed to allow for patient stratification, which is critically important to improve the clinical translation of cancer nanomedicines. The outcomes of the different project lines in Meta-Targeting will - alone and especially together - be truly transformative: they will contribute to scientific and clinical progress in nanomedicine, in tumor-targeted drug delivery, in immunotherapy, and in the treatment of metastatic cancer.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-COG - Consolidator Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2019-COG

See all projects funded under this call

Host institution

UNIVERSITAETSKLINIKUM AACHEN
Net EU contribution
€ 1 979 375,00
Address
Pauwelsstrasse 30
52074 Aachen
Germany
Region
Nordrhein-Westfalen Köln Städteregion Aachen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 979 375,00

Beneficiaries (1)